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Phosphopantetheine adenylyltransferase (PPAT) catalyzes the fourth of ﬁve
steps in the coenzyme A biosynthetic pathway, reversibly transferring an
adenylyl group from ATP onto 40-phosphopantetheine to yield dephospho-
coenzyme A and pyrophosphate. Burkholderia pseudomallei is a soil- and water-
borne pathogenic bacterium and the etiologic agent of melioidosis, a potentially
fatal systemic disease present in southeast Asia. Two crystal structures are
presented of the PPAT from B. pseudomallei with the expectation that, because
of the importance of the enzyme in coenzyme A biosynthesis, they will aid in the
search for defenses against this pathogen. A crystal grown in ammonium sulfate
yielded a 2.1 A ˚ resolution structure that contained dephospho-coenzyme Awith
partial occupancy. The overall structure and ligand-binding interactions are
quite similar to other bacterial PPAT crystal structures. A crystal grown at low
pH in the presence of coenzyme A yielded a 1.6 A ˚ resolution structure in the
same crystal form. However, the experimental electron density was not
reﬂective of fully ordered coenzyme A, but rather was only reﬂective of an
ordered 40-diphosphopantetheine moiety.
1. Introduction
Coenzyme A is biosynthesized in ﬁve invariant steps from panto-
thenate (vitamin B5), cysteine and ATP (Robishaw & Neely, 1985).
The fourth step in the biosynthetic pathway is the adenylylation of
40-phosphopantetheine using ATP to form dephospho-coenzyme A
and pyrophosphate (Martin & Drueckhammer, 1993). This reversible
reaction is catalyzed by phosphopantetheine adenylyltransferase,
which is also named pantetheine-phosphate adenylyltransferase or
PPAT. Dephospho-coenzyme A synthesis by PPAT is believed to be
the rate-limiting step in CoA biosynthesis. Because of the importance
of coenzyme A in the citric acid cycle as well as fatty-acid synthesis,
coenzyme A biosynthetic proteins are believed to be potential drug
targets for infectious disease organisms and PPAT inhibitors have
been developed (Zhao et al., 2003).
The ﬁrst PPAT crystal structures were solved from Escherichia coli
(PDB entries 1qjc, 1gn8, 1h1t and 1b6t; Izard, 2002, 2003; Izard &
Geerlof, 1999; Izard et al., 1999) and were followed by a number of
other PPAT crystal structures from Archaeoglobus fulgidus (PDB
entry 3do8; R. Zhang, R. Wu, R. Jedrzejczak & A. Joachimiak,
unpublished work), Bacillus subtilis (PDB entry 1o6b; Badger et al.,
2005), Mycobacterium tuberculosis (PDB entry 1tfu; Morris & Izard,
2004), Thermotoga maritima (PDB entry 1vlh; Joint Center for
Structural Genomics, unpublished work), Thermus thermophilus
(PDB entry 1od6; Takahashi et al., 2004), Staphylococcus aureus
(PDB entry 3f3m; Lee et al., 2009) and Yersinia pestis (PDB entries
3l92 and 3l93; J. Osipiuk, N. Maltseva, M. Makowska-grzyska, K.
Kwon, W. F. Anderson & A. Joachimiak, unpublished work). On the
whole, these structures include apo enzymes (PDB entries 3l93, 3do8
and 1tfu), a variety of substrate-bound states (e.g. 40-phospho-
pantetheine in PDB entries 1od6 and 1qjc and ATP in PDB entry
1gn8) and product states (dephospho-coenzyme A), as well as non-
native states (e.g. ADP, coenzyme A).Burkholderia pseudomallei is a pathogenic bacterium that causes
the potentially fatal disease melioidosis (Cheng, 2010). B. pseudo-
mallei is closely related to B. mallei, the organism that causes glan-
ders, and more distantly related to B. cenocepacia, an organism that
causes acute infections in patients with cystic ﬁbrosis. In B. pseudo-
mallei, the coaD gene encodes the 166-residue protein Bp PPAT,
although it has not yet been shown that Bp PPAT is essential for
B. pseudomallei. Here, we present two crystal structures of Bp PPAT.
One structure appears to contain dephospho-coenzyme A from the
expression host carried through the protein puriﬁcation. A second
structure grown in the presence of coenzyme A only showed signif-
icant electron density for the 40-diphosphopantetheine moiety and
weaker electron density for the adenine nucleobase.
2. Methods
2.1. Protein expression and purification
Phosphopantetheine adenylyltransferase from B. pseudomallei
strain 1710b (NCBI YP 332162.1; coaD gene BURPS1710B_0748;
UniProt Q3JW91; Pfam ID PF01467; EC 2.7.7.3) spanning the full-
length protein from residues 1–166 (‘ORF’) was cloned into a
pAVA0421 vector encoding an N-terminal histidine-afﬁnity tag
followed by the human rhinovirus 3C protease-cleavage sequence
(the entire tag sequence is MAHHHHHHMGTLEAQTQGPGS-
ORF) using ligation-independent cloning (Aslanidis & de Jong, 1990;
Kelley et al., 2011). Phosphopantetheine adenylyltransferase was
expressed in E. coli using BL21(DE3)R3 Rosetta cells and auto-
induction medium (Studier, 2005) in a LEX Bioreactor (Leibly et al.,
2011). The frozen cells were resuspended in lysis buffer (25 mM
HEPES pH 7.0, 500 mM NaCl, 5% glycerol, 30 mM imidazole,
0.025% azide, 0.5% CHAPS, 10 mM MgCl2,1 m M TCEP,
250 ng ml
 1 protease inhibitor AEBSFand 0.05 mgm l
 1 lysozyme) at
277 K. The resuspended cell pellet was disrupted on ice for 30 min
with a Virtis sonicator (Virtis 408912; settings: 100 W power with
alternating cycles of 15 s pulse-on and 15 s pulse-off). The cell debris
was incubated with 20 ml Benzonase nuclease (25 units ml
 1) at room
temperature for 45 min and clariﬁed by centrifugation on a Sorvall
SLA-1500 at 14 000 rev min
 1 for 75 min at 277 K. The protein was
puriﬁed from the clariﬁed cell lysate by immobilized metal-afﬁnity
chromatography (IMAC) on a His Trap FF 5 ml column (GE
Healthcare) equilibrated with binding buffer (25 mM HEPES pH 7.0,
0.5 M NaCl, 5% glycerol, 30 mM imidazole, 0.025% azide, 1 mM
TCEP) at 277 K. The recombinant protein was eluted with binding
buffer supplemented with 250 mM imidazole. The afﬁnity tag was
removed by incubation with His6-MBP-3C protease at 277 K during
dialysis into binding buffer overnight, followed by a subtractive
nickel gravity-ﬂow column with the buffers described above. The now
tagless protein (sequence GPGS-ORF) was collected in the ﬂow-
through and was further resolved by size-exclusion chromatography
(SEC) using a HiLoad 26/60 Superdex 200 column (GE Healthcare)
at 277 K. Pure fractions collected in SEC buffer (25 mM HEPES pH
7.0, 0.5 M NaCl, 2 mM DTT, 0.025% azide and 5% glycerol) as a
single peak were pooled. During concentration at 277 K, the protein
was observed to precipitate. 10 mM ATP (Sigma–Aldrich, >99%
purity) was added to the protein solution, which allowed concentra-
tion of the protein to 5.5 mg ml
 1. The protein sample was ﬂash-
frozen and stored at 193 K. A second batch of protein was prepared
in which the afﬁnity tag was not removed. This puriﬁcation used more
optimal buffers identiﬁed by thermal denaturation studies. To
improve the buffer conditions for the second puriﬁcation, nickel
IMAC-puriﬁed protein from the ﬁrst batch was subjected to an 80-
buffer thermal denaturation screen. 12.5 mg protein was added to
26 ml buffer mixed with SYPRO Orange protein dye (Invitrogen).
Thermal denaturation was performed over a gradient from 293 to
373 K as described by Crowther et al. (2010). The buffer conditions
that showed the largest positive shift in thermal denaturation
temperature were selected for use in puriﬁcation of the second batch
of protein. Cells were lysed as in the ﬁrst puriﬁcation batch except
in an optimized lysis buffer (10 mM Tris pH 8.0, 0.5 M NaCl, 5%
glycerol, 30 mM imidazole, 0.025% azide, 0.5% CHAPS, 10 mM
MgCl2, 250 ng ml
 1 AEBSF and 0.05 mgm l
 1 lysozyme). IMAC was
performed as in the ﬁrst preparation except with optimized binding
buffer (10 mM Tris pH 8.0, 0.5 M NaCl, 5% glycerol, 30 mM imida-
zole, 1 mM MgCl2). The protein was eluted with optimized binding
buffer supplemented with 250 mM imidazole. SEC was performed
with an optimized SEC buffer (10 mM Tris pH 8.0, 450 mM NaCl, 5%
glycerol, 1 mM MgCl2). Fractions containing the protein were pooled,
coenzyme A (Sigma-Aldrich catalog No. C3144, >85% purity) was
added to 1 mM and the protein was concentrated to 19.2 mg ml
 1
with good solubility. The protein sample was ﬂash-frozen and stored
at 193 K prior to crystallography. Each protein sample was >95%
pure as determined by denaturing SDS–PAGE.
2.2. Crystallization
Sitting-drop vapour-diffusion crystallization trials were set up at
289 K using either the JCSG+, PACT (Newman et al., 2005) or Cryo
Full sparse-matrix screens from Emerald BioSystems or the Crystal
Screen HT sparse-matrix screen from Hampton Research. Bp PPAT
stock solutions (0.4 ml) were mixed with reservoir solution (0.4 ml)
and equilibrated against reservoir solution (100 ml) using 96-well
Compact Jr plates from Emerald BioSystems. Crystals grew in several
conditions, but those used in X-ray data-collection and structure
determination were obtained from Crystal Screen HT conditions C8
(protein sequence GPGS-ORF, 5.5 mg ml
 1 protein solution equili-
brated against 2.0 M ammonium sulfate, which resulted in PDB entry
3pxu) and F1 (protein sequence MAHHHHHHMGTLEAQTQG-
PGS-ORF, 19.2 mg ml
 1 protein solution equilibrated against 0.2 M
ammonium sulfate, 0.1 M sodium acetate pH 4.6, 30% PEG 2000
MME, which resulted in PDB entry 3k9w).
2.3. Data collection and structure determination
The crystals grown in the presence of 2.0 M ammonium sulfate
were harvested after cryoprotection in lithium sulfate. A data set was
collected in-house using a Rigaku SuperBright FR-E+ rotating-anode
X-ray generator with Osmic VariMax HF optics and a Saturn 944+
CCD detector (Table 1). The data were reduced with HKL-2000
(Minor et al., 2006). The structure was solved by molecular replace-
ment using Phaser (McCoy et al., 2007) from the CCP4 suite (Winn et
structural communications
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Table 1
Data-collection statistics.
Values in parentheses indicate the values for the highest of 20 resolution shells.
Ligand Dephospho-CoA Partial CoA
Space group I432 I432
Unit-cell parameters (A ˚ ) a = b = c = 134.2 a = b = c = 134.4
Wavelength (A ˚ ) 1.5418 0.97953
Resolution range (A ˚ ) 50–2.1 (2.18–2.10) 50–1.6 (1.66–1.60)
Unique reﬂections 12286 27383
Multiplicity 28.3 (22.4) 10.7 (9.1)
Completeness (%) 99.7 (98.1) 99.0 (100)
Rmerge† 0.084 (0.519) 0.067 (0.555)
Mean I/ (I) 44.5 (6.6) 32.8 (4.0)
† Rmerge =
P
h
P
i jIiðhÞ h IðhÞij=
P
h
P
i IiðhÞ.al., 2011) using the protein model of molecule A of the E. coli PPAT
crystal structure (PDB entry 1b6t; Izard & Geerlof, 1999) as the
search model. The structure was initially rebuilt with ARP/wARP
(Langer et al., 2008), followed by numerous reiterative rounds of
reﬁnement in REFMAC (Murshudov et al., 1997) and manual
building in Coot (Emsley & Cowtan, 2004). The ﬁnal model contained
one copy of Bp PPAT spanning residues Ser0 (from the expression-
tag remnant) through Ala91 and residues Phe95 through Ala161, two
sulfate ions, two glycerol molecules, 90 water molecules and depho-
spho-coenzyme A. The low-pH crystals were harvested after cryo-
protection with 20% ethylene glycol and 80% precipitant. A data set
was collected on the Canadian Light Source beamline 08ID-1 (Table
1). The data were reduced with HKL-2000 (Minor et al., 2006) andthe
structure was solved by reﬁnement against the protein model of the
ﬁrst structure. The ﬁnal model was produced after numerous
reiterative rounds of reﬁnement in REFMAC (Murshudov et al.,
1997) and manual building in Coot (Emsley & Cowtan, 2004). The
ﬁnal model contained one copy of Bp PPAT spanning residues Ser0
through Ala161, a sulfate ion, an acetate ion, a polyethylene glycol
molecule, 137 water molecules, adenine and 40-dipho-
sphopantetheine. For both structures water molecules were built with
stringent criteria of electron density above 1.2  in the 2|Fo|   |Fc| map
and one or more hydrogen-bonding partners. Although the Rmerge
values for both structures (Table 1) may be high by some standards,
inclusion of data to higher resolution improved the experimental
electron-density maps for both structures and allowed improved
model building relative to more conservative resolution limits. The
ﬁnal model for each structure showed good geometry and ﬁtness
(Table 2) according to analysis with MolProbity (Chen et al., 2010).
3. Results and discussion
3.1. Overall structure
Bp PPAT has approximately 42–50% sequence identity (64–75%
similarity) to PPATs from B. subtilis, E. coli, M. tuberculosis,
T. maritima, T. thermophilus and S. aureus (Fig. 1). In contrast, Bp
PPAT has signiﬁcantly lower sequence identity to other PPATs such
as those from A. fulgidus and Y. pestis. The crystal structure of Bp
PPAT features a Rossmann fold, which is known to bind di-
nucleotides as well as GTP and ATP. One copy of Bp PPAT was
observed in the asymmetric unit, indicating that the other ﬁve copies
that comprise the biologically active homohexamer are crystallo-
graphically equivalent. The homohexameric quaternary structure of
Bp PPAT (Fig. 2a) is similar to other members of the nucleotidyl-
transferase superfamily and all other reported PPAT crystal struc-
tures.
3.2. Product state
From a protein sample concentrated in the presence of ATP, we
solved a 2.1 A ˚ resolution crystal structure of Bp PPAT (Table 1).
This structure had clear evidence but weak electron density for
dephospho-coenzyme A in the active site, indicating that dephospho-
structural communications
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Table 2
Reﬁnement and model statistics.
Values in parentheses indicate the values for the highest of 20 resolution shells.
Ligand Dephospho-CoA Partial CoA
Resolution range (A ˚ ) 50–2.1 (2.18–2.10) 50–1.6 (1.66–1.60)
Rcryst 0.202 (0.204) 0.192 (0.229)
Rfree† 0.242 (0.315) 0.207 (0.266)
R.m.s.d. bonds (A ˚ ) 0.015 0.008
R.m.s.d. angles ( ) 1.463 1.193
Protein atoms 1254 1360
Nonprotein atoms 155 192
Mean B factor (A ˚ 2) 30.0 15.1
Ligand B factor (A ˚ 2) 33.2 14.5
Residues in favored region (%) 98.7 99.4
Residues in allowed region (%) 100 100
MolProbity score [percentile] 1.36 [99th] 1.47 [90th]
PDB code 3pxu 3k9w
† Rfree =
P
h
   jFobsj j Fcalcj
   =
P
h jFobs. The free R factor was calculated using 5% of the
reﬂections omitted from the reﬁnement (Winn et al., 2011).
Figure 1
Multiple sequence alignment of bacterial PPATs. Sequences are shown from B. pseudomallei (Bp PPAT; PDB entry 3pxu; present study), E. coli (PDB entry 1b6t; Izard &
Geerlof, 1999), Y. pestis (PDB entry 3l93; Osipiuk et al., unpublished work), T. maritima (PDB entry 1vlh; Joint Center for Structural Genomics, unpublished work),
M. tuberculosis (PDB entry 1tfu; Morris & Izard, 2004), B. subtilis (PDB entry 1o6b; Badger et al., 2005) and T. thermophilus (PDB entry 1od6; Takahashi et al., 2004).
 -Helices and  -sheets from the Bp PPAT structure are shown as magenta cylinders and yellow arrows, respectively. The side chains of Thr9, Arg87 and Glu98 interact with
dephospho-coenzyme A in the 3pxu structure. This ﬁgure was prepared with Geneious (Drummond et al., 2010).structural communications
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coenzyme A was only partially occupied. Coenzyme A metabolites
are known to exist at signiﬁcant concentrations in E. coli (Jackowski
& Rock, 1984) and thus it is not surprising to see dephospho-
coenzyme A carried through the puriﬁcation from the expression
host. Reﬁnement with the occupancy of dephospho-coenzyme A set
to 0.5 (i.e. 50%) resulted in crystallographic B factors that were in line
with those of the surrounding protein atoms ( 30 A ˚ 2). In the E. coli
PPAT crystal structure dephospho-coenzyme A was present in only
one trimer, while the other trimer was unliganded (Izard & Geerlof,
1999). Overall, the Bp PPATand E. coli PPAT dephospho-coenzyme
A-bound crystal structures are quite similar (C
  r.m.s.d. of 1.00 A ˚ ;
Fig. 2b). Dephospho-coenzyme A forms many packing interactions
and hydrogen bonds with backbone amides in the active site, but also
makes hydrogen bonds to the side chains of the conserved residues
Thr9 (which is conserved as a threonine or serine), Arg87 (which is
conserved as an arginine or lysine) and Glu98 (see Fig. 1 for sequence
conservation). Differences were observed between the E. coli PPAT
unliganded and coenzyme A-bound protomers, especially the
movement of residues at the N-terminal side of  4. Equivalent resi-
dues in the Bp PPAT structure (92–94) are disordered in the product
state and several neighboring residues have disordered side chains
(Phe95, Phe99 and Tyr107; Fig. 2b). It is unknown whether Bp PPAT
follows asymmetric ligation in the same manner as E. coli PPAT
(Izard & Geerlof, 1999) and M. tuberculosis PPAT (Morris & Izard,
2004).
3.3. Structure at low pH
We prepared a second Bp PPAT protein sample that contained the
full-length expression tag and which was concentrated in the presence
of coenzyme A (see x2.1). From this sample, we obtained a crystal at
low pH (4.6) that resulted in a 1.6 A ˚ resolution data set of the same
crystal form as the dephospho-coenzyme-A-bound structure
(Table 1). Since this structure obtained from a protein sample
containing the N-terminal His tag and the product-state structure
described above resulted in isomorphous crystal forms, itappears that
the presence of the N-terminal His tag does not affect the structure of
Bp PPAT. This data set had omit electron density reminiscent of
coenzyme A, with strong density for the pantetheine and diphosphate
moieties, but had little or no omit electron density for what should
have been the adenine ring, ribose ring and 30-phosphate (Figs. 3a and
Figure 2
Crystal structure of Bp PPAT solved at 2.1 A ˚ resolution. (a) Biologically relevant hexameric structure of Bp PPAT from a crystal structure with bound dephospho-coenzyme
A solved at 2.1 A ˚ resolution. (b) Overlay of the dephospho-coenzyme A-bound structures of Bp PPAT (green) and E. coli PPAT (PDB entry 1b6t, magenta; Izard & Geerlof,
1999). Green spheres are used to illustrate disordered residues in the Bp PPAT crystal structures. Figs. 2 and 3 were prepared using PyMOL (DeLano, 2002).3b). Reﬁnement with coenzyme A in the active site resulted in poor
geometry of coenzyme A bonds, with a strong negative peak in the
|Fo|   |Fc| map centered on C4–C5 of the ribose ring. This strong
negative peak led us to believe that coenzyme A had been hydrolyzed
or was disordered beyond the diphosphate moiety. Reﬁnement with
40-diphosphopantetheine gave a signiﬁcantly better ﬁt with excellent
electron density (Fig. 3c) and crystallographic B factors that were on
a par with the surrounding protein atoms (Table 2). We noted modest
omit electron density for the adenine ring, which was also modelled
(Fig. 3c) and resulted in reasonable electron density and somewhat
higher average B factors than the surrounding protein atoms,
implying that the adenine ring may only be partially occupied. The
remaining electron-density features ﬁt well as three waters and a
sulfate ion (the crystal grew in the presence of 0.2 M sulfate ion).
Moreover, the adenine and 40-diphosphopantetheine components
overlay well with the Bp PPAT structure solved in the presence of
dephospho-coenzyme A (Fig. 3d). We note that the feature modelled
as a sulfate ion is unlikely to be the 30-phosphate of coenzyme A,
since it appears off the 20 position when overlaid with the structure
containing dephospho-coenzyme A.
4. Conclusions
We obtained high-resolution crystal structures of phospho-
pantetheine adenylyltransferase from B. pseudomallei with the
reaction product dephospho-coenzyme A and from a second crystal
obtained in the presence of coenzyme A. The structure obtained of
the product state is similar to other bacterial PPAT crystal structures
obtained in the product state. The crystal grown at low pH in the
presence of coenzyme A resulted in a structure solution that showed
clear electron density for the 40-diphosphopantetheine and adenine
structural communications
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Figure 3
Crystal structure of Bp PPAT solved at 1.6 A ˚ resolution. (a) Monomeric structure of Bp PPAT in ribbon format with molecular-surface rendering in light transparency.
Active-site components are modelled in stick representation and selected waters are shown as spheres. The active-site ligand-omit density map (|Fo|   |Fc|) is shown as a
green mesh contoured at 3.0 .( b) Close-up of the active site. The ﬁnal protein model is shown in ribbon representation along with 40-diphosphopantetheine, adenine and a
sulfate ion in stick representation and selected waters as red spheres. The active-site ligand-omit electron-density map (|Fo|   |Fc|) is shown as a green mesh contoured at
3.0 .( c) Active site as in (b) with the 2|Fo|   |Fc| electron-density map shown as a blue mesh contoured at 1.0 .( d) Overlay of the ﬁnal reﬁned structure of Bp PPAT from (c)
along with the structure of Bp PPAT-bound dephospho-coenzyme A solved at 2.1 A ˚ resolution with coloring as in Fig. 2(b).moieties. It is unknown whether the lack of electron density for the
ribose ring and 30-phosphate resulted from hydrolysis under the
crystallographic conditions, hydrolysis by the enzyme or is reﬂective
of disorder of the coenzyme.
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